Skip to content

Author

Yongxiang Lu

1 paper indexed here

We haven’t gathered this author’s papers yet. Follow them and we’ll fetch their work.

Not the right person? Other researchers publish under this name.

Aug 2026

Empagliflozin inhibits cardiac hypertrophy via a mechanism involving integrin signalling.

BACKGROUND AND PURPOSE Pathological cardiac hypertrophy precipitates heart failure. Empagliflozin (EMPA), a sodium-glucose cotransporter 2 (SGLT2) inhibitor, confers cardiovascular protection beyond glycaemic control, but the molecular basis of its direct anti-hypertrophic action remains undefined. EXPERIMENTAL APPRO...

Gan Qiao, Roudian Lin, Yongxiang Lu et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.